Next Article in Journal
Occurrence and Exposure Assessment of Aflatoxins and Deoxynivalenol in Cereal-Based Baby Foods for Infants
Previous Article in Journal
Acute Kidney Injury Induced by Bothrops Venom: Insights into the Pathogenic Mechanisms
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Toxins 2019, 11(3), 149;

Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae

Laboratorio de Investigación Química y Farmacológica de Productos Naturales, Facultad de Química, Universidad Autónoma de Querétaro, Querétaro 76010, Mexico
Veteria Labs, S.A. de C.V. Lucerna 7, Col. Juárez, Del. Cuauhtémoc, Ciudad de México 06600, Mexico
Inosan Biopharma, S.A. Arbea Campus Empresarial, Edificio 2, Planta 2, Carretera Fuencarral a Alcobendas, Km 3.8, 28108 Madrid, Spain
Author to whom correspondence should be addressed.
Received: 21 January 2019 / Revised: 26 February 2019 / Accepted: 27 February 2019 / Published: 5 March 2019
(This article belongs to the Section Animal Venoms)
PDF [1395 KB, uploaded 5 March 2019]


The European continent is inhabited by medically important venomous Viperinae snakes. Vipera ammodytes, Vipera berus, and Vipera aspis cause the greatest public health problems in Europe, but there are other equally significant snakes in specific regions of the continent. Immunotherapy is indicated for patients with systemic envenoming, of which there are approximately 4000 annual cases in Europe, and was suggested as an indication for young children and pregnant women, even if they do not have systemic symptoms. In the present study, the safety and venom-neutralizing efficacy of Inoserp Europe—a new F(ab’)2 polyvalent antivenom, designed to treat envenoming by snakes in the Eurasian region—were evaluated. In accordance with World Health Organization recommendations, several quality control parameters were applied to evaluate the safety of this antivenom. The venom-neutralizing efficacy of the antivenom was evaluated in mice and the results showed it had appropriate neutralizing potency against the venoms of several species of Vipera, Montivipera, and Macrovipera. Paraspecificity of the antivenom was demonstrated as well, since it neutralized venoms of species not included in the immunization schemes and contains satisfactory levels of total proteins and F(ab’)2 fragment concentration. Therefore, this new polyvalent antivenom could be effective in the treatment of snake envenoming in Europe, including Western Russia and Turkey. View Full-Text
Keywords: Viperinae; Vipera; Macrovipera; Montivipera; neutralization; paraspecificity; antivenom Viperinae; Vipera; Macrovipera; Montivipera; neutralization; paraspecificity; antivenom

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

García-Arredondo, A.; Martínez, M.; Calderón, A.; Saldívar, A.; Soria, R. Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae. Toxins 2019, 11, 149.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top